Leerink Partnrs Brokers Decrease Earnings Estimates for EWTX

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Equities researchers at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Edgewise Therapeutics in a research report issued on Monday, March 3rd. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.45) per share for the quarter, down from their prior estimate of ($0.40). The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share. Leerink Partnrs also issued estimates for Edgewise Therapeutics’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.20) EPS and FY2026 earnings at ($2.53) EPS.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03).

Several other brokerages also recently issued reports on EWTX. Wedbush lifted their target price on Edgewise Therapeutics from $44.00 to $45.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Royal Bank of Canada restated an “outperform” rating and set a $56.00 target price on shares of Edgewise Therapeutics in a research report on Tuesday. Evercore ISI boosted their price target on shares of Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 17th. Truist Financial increased their price objective on shares of Edgewise Therapeutics from $33.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, November 27th. Finally, Stifel Nicolaus started coverage on Edgewise Therapeutics in a report on Wednesday, January 22nd. They issued a “hold” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Edgewise Therapeutics has an average rating of “Moderate Buy” and an average price target of $44.71.

Edgewise Therapeutics Stock Performance

Shares of EWTX stock opened at $26.71 on Wednesday. The stock has a fifty day simple moving average of $26.81 and a two-hundred day simple moving average of $27.76. The firm has a market capitalization of $2.53 billion, a PE ratio of -17.81 and a beta of 0.20. Edgewise Therapeutics has a 52-week low of $14.90 and a 52-week high of $38.12.

Institutional Trading of Edgewise Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Baker BROS. Advisors LP grew its holdings in shares of Edgewise Therapeutics by 5.4% in the fourth quarter. Baker BROS. Advisors LP now owns 6,155,940 shares of the company’s stock worth $164,364,000 after purchasing an additional 315,881 shares during the last quarter. Janus Henderson Group PLC boosted its position in Edgewise Therapeutics by 9.3% in the 4th quarter. Janus Henderson Group PLC now owns 4,983,940 shares of the company’s stock valued at $133,044,000 after buying an additional 425,421 shares during the period. Paradigm Biocapital Advisors LP grew its stake in Edgewise Therapeutics by 61.1% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,493,929 shares of the company’s stock worth $119,988,000 after acquiring an additional 1,704,757 shares in the last quarter. Braidwell LP increased its position in shares of Edgewise Therapeutics by 19.1% during the fourth quarter. Braidwell LP now owns 2,332,196 shares of the company’s stock worth $62,270,000 after acquiring an additional 373,886 shares during the period. Finally, Deerfield Management Company L.P. Series C raised its stake in shares of Edgewise Therapeutics by 16.7% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,078,509 shares of the company’s stock valued at $55,496,000 after acquiring an additional 297,503 shares in the last quarter.

Insider Activity

In other Edgewise Therapeutics news, insider Marc Semigran sold 29,709 shares of the business’s stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $29.69, for a total transaction of $882,060.21. Following the transaction, the insider now owns 6,716 shares in the company, valued at $199,398.04. The trade was a 81.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Alan J. Russell sold 100,000 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $27.37, for a total transaction of $2,737,000.00. Following the completion of the sale, the insider now directly owns 14,863 shares in the company, valued at approximately $406,800.31. This represents a 87.06 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 164,545 shares of company stock worth $4,605,305. 24.11% of the stock is currently owned by corporate insiders.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.